FDA official quits over Plan B decision

Share this article:
The FDA's Office of Women's Health (OWH) director has resigned in protest over the agency's refusal to permit OTC sales of Barr's Plan B emergency contraceptive.
OWH director Susan Wood announced her resignation in an e-mail to agency colleagues.
The FDA declined to comment on Wood's departure.
The agency announced it would defer a decision on the politically sensitive drug, pending a 60-day public comment period. That decision came despite an earlier promise to Congress from FDA Commissioner Lester Crawford to make a final decision on Plan B by Sept. 1.
Senators Hillary Clinton (D-N.Y.) and Patty Murray (D-Wash.) placed a hold on Crawford's nomination to commissioner in June, demanding a yes or no decision on the drug, but relented in July when he issued a Sept. 1 deadline.
"It is deeply disturbing that an agency long recognized for making decisions based on sound science has become so politicized that one of its most widely respected, long-serving veterans would feel disillusioned enough to quit in protest," Clinton and Murray said in a joint statement.
Share this article:
You must be a registered member of MMM to post a comment.

Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.